Ameritas Investment Partners’s KalVista Pharmaceuticals KALV Stock Holding History

Ameritas Investment Partners’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$64.1K	Hold	3,186	–	–	﹤0.01%	1946
2025 Q4	$51.5K	Sell	3,186 -545	-15%	-$7.22K	﹤0.01%	2098
2025 Q3	$45.4K	Hold	3,731	–	–	﹤0.01%	2199
2025 Q2	$42.2K	Hold	3,731	–	–	﹤0.01%	2292
2025 Q1	$43.1K	Hold	3,731	–	–	﹤0.01%	2192
2024 Q4	$31.6K	Hold	3,731	–	–	﹤0.01%	2431
2024 Q3	$43.2K	Hold	3,731	–	–	﹤0.01%	2278
2024 Q2	$44K	Buy	3,731 +1,263	+51%	+$14.7K	﹤0.01%	2217
2024 Q1	$29.3K	Hold	2,468	–	–	﹤0.01%	2419
2023 Q4	$30.2K	Hold	2,468	–	–	﹤0.01%	2396
2023 Q3	$23.8K	Buy	2,468 +918	+59%	+$9.38K	﹤0.01%	2456
2023 Q2	$13.9K	Hold	1,550	–	–	﹤0.01%	2756
2023 Q1	$12.2K	Hold	1,550	–	–	﹤0.01%	2656
2022 Q4	$12.3K	Hold	1,550	–	–	﹤0.01%	2752
2022 Q3	$22K	Hold	1,550	–	–	﹤0.01%	2481
2022 Q2	$15K	Hold	1,550	–	–	﹤0.01%	2686
2022 Q1	$23K	Hold	1,550	–	–	﹤0.01%	2494
2021 Q4	$21K	Hold	1,550	–	–	﹤0.01%	2622
2021 Q3	$27K	Hold	1,550	–	–	﹤0.01%	2532
2021 Q2	$37K	Hold	1,550	–	–	﹤0.01%	2385
2021 Q1	$40K	Buy	1,550 +520	+50%	+$13.7K	﹤0.01%	2210
2020 Q4	$20K	Hold	1,030	–	–	﹤0.01%	2471
2020 Q3	$13K	Hold	1,030	–	–	﹤0.01%	2592
2020 Q2	$12K	Hold	1,030	–	–	﹤0.01%	2629
2020 Q1	$8K	Hold	1,030	–	–	﹤0.01%	2638
2019 Q4	$18K	Hold	1,030	–	–	﹤0.01%	2461
2019 Q3	$12K	Hold	1,030	–	–	﹤0.01%	2658
2019 Q2	$23K	Buy	+1,030	New	+$24.2K	﹤0.01%	2368

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Ameritas Investment Partners's KALV Position: Q1 2026 in Review

Ameritas Investment Partners held its KalVista Pharmaceuticals (KALV) position steady in Q1 2026 at 3,186 shares worth $64.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1946.

Ameritas Investment Partners first reported a position in KALV in Q2 2019 and has held it in 28 quarters since. 183 funds tracked by Wall St. Rank hold KALV as of Q1 2026.

Ameritas Investment Partners held 3,186 shares of KalVista Pharmaceuticals worth $64.1K as of Q1 2026.
Ameritas Investment Partners left its KalVista Pharmaceuticals share count unchanged in Q1 2026.
KalVista Pharmaceuticals made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #1946 holding.
Ameritas Investment Partners first reported a position in KalVista Pharmaceuticals in Q2 2019 and has held it in 28 quarters since.
183 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.